WHO recommends groundbreaking malaria vaccine for children at risk.
The World Health Organization (WHO) is recommending widespread use of the RTS,S/AS01 (RTS,S) malaria vaccine among children.
WHO Director-General Dr Tedros Adhanom Ghebreyesus made this announcement. He noted this as a historic moment.
The WHO is recommending it for children in sub-Saharan Africa and in other regions with moderate to high P. falciparum malaria transmission.
WHO recommends groundbreaking malaria vaccine for children at risk
Furthermore, the recommendation remains based on results from an ongoing pilot programme in Ghana, Kenya and Malawi that has reached more than 800 000 children since 2019.
Moreover, the DG WHO said the long-awaited malaria vaccine for children is a breakthrough for science, child health and malaria control.
“Using this vaccine on top of existing tools to prevent malaria could save tens of thousands of young lives each year.”
Malaria remains a primary cause of childhood illness and death in sub-Saharan Africa. More than 260 000 African children under the age of five die from malaria annually.
In recent years, WHO and its partners have been reporting a stagnation in progress against the deadly disease.
According to Dr Matshidiso Moeti, WHO Regional Director for Africa, for centuries, malaria has stalked sub-Saharan Africa, causing immense personal suffering.
“We have long hoped for an effective malaria vaccine and now for the first time ever, we have such a vaccine recommended for widespread use.
Today’s recommendation offers a glimmer of hope for the continent which shoulders the heaviest burden of the disease and we expect many more African children to be protected from malaria and grow into healthy adults.”
WHO recommendation for the RTS,S malaria vaccine
Based on the advice of two WHO global advisory bodies, one for immunization and the other for malaria, the Organization recommends that:
Furthermore, WHO recommends that in the context of comprehensive malaria control the RTS,S/AS01 malaria vaccine be used for the prevention of P. falciparum malaria in children living in regions with moderate to high transmission. WHO defines such areas, regions.
TS,S/AS01 malaria vaccine should be provided in a schedule of 4 doses in children from 5 months of age for the reduction of malaria disease and burden.
Summary of key findings of the malaria vaccine pilots
Key findings of the pilots informed the recommendation based on data and insights generated from two years of vaccination in child health clinics in the three pilot countries, implemented under the leadership of the Ministries of Health of Ghana, Kenya and Malawi.
Feasible to deliver: Vaccine introduction is feasible, improves health and saves lives, with good and equitable coverage of RTS,S seen through routine immunization systems.
Moreover, this occurred even in the context of the COVID-19 pandemic.
Reaching the unreached: RTS,S increases equity in access to malaria prevention.
Data from the pilot programme showed that more than two-thirds of children in the 3 countries who are not sleeping under a bednet are benefitting from the RTS,S vaccine.
Over 90% of children benefitting
Layering the tools results in over 90% of children benefitting from at least one preventive intervention (insecticide treated bednets or the malaria vaccine).
Strong safety profile: To date, more than 2.3 million doses of the vaccine administered in 3 African countries – the vaccine has a favorable safety profile.
Furthermore, no negative impact on uptake of bednets, other childhood vaccinations, or health seeking behavior for febrile illness.
In areas where the vaccine introduced, no decrease reported in the use of insecticide-treated nets, uptake of other childhood vaccinations or health seeking behavior for febrile illness.
Besides, high impact in real-life childhood vaccination settings:
Specially, significant reduction (30%) in deadly severe malaria, even when introduced in areas where insecticide-treated nets remain widely used and good access to diagnosis and treatment.
Modelling estimates that the vaccine is cost effective in areas of moderate to high malaria transmission.